U.S. FDA Approves VIZIMPRO® (dacomitinib) Long

Pfizer, Inc.NYSE

Description

⋅ Sep 28, 2018 4:33 PM

PFE: Pfizer Inc.
2018-09-27 17:41:00
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

Beyond Technical Analysis

Comments

ForExtraPips

⋅ Sep 30, 2018 6:40 PM

Good to hear. I bought a call @ 43.00 on the 17th of Sep. Targeting between 52.00 and 55.00 by the end of this year.